JPWO2019183248A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019183248A5 JPWO2019183248A5 JP2020551263A JP2020551263A JPWO2019183248A5 JP WO2019183248 A5 JPWO2019183248 A5 JP WO2019183248A5 JP 2020551263 A JP2020551263 A JP 2020551263A JP 2020551263 A JP2020551263 A JP 2020551263A JP WO2019183248 A5 JPWO2019183248 A5 JP WO2019183248A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rna
- sequence
- replication
- origin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000010076 replication Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 36
- 230000001419 dependent effect Effects 0.000 claims description 30
- 239000013612 plasmid Substances 0.000 claims description 26
- 108091030084 RNA-OUT Proteins 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 108020005091 Replication Origin Proteins 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 7
- 240000007019 Oxalis corniculata Species 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 239000013607 AAV vector Substances 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 12
- 241000588724 Escherichia coli Species 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 210000000349 chromosome Anatomy 0.000 claims 3
- 238000000855 fermentation Methods 0.000 claims 3
- 230000004151 fermentation Effects 0.000 claims 3
- 230000003252 repetitive effect Effects 0.000 claims 3
- 102000008579 Transposases Human genes 0.000 claims 2
- 108010020764 Transposases Proteins 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102200071165 rs193922538 Human genes 0.000 claims 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 2
- 241001505262 Enterobacteria phage Pol Species 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024110895A JP2024138410A (ja) | 2018-03-21 | 2024-07-10 | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645892P | 2018-03-21 | 2018-03-21 | |
| US62/645,892 | 2018-03-21 | ||
| PCT/US2019/023209 WO2019183248A1 (en) | 2018-03-21 | 2019-03-20 | Viral and non-viral nanoplasmid vectors with improved production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024110895A Division JP2024138410A (ja) | 2018-03-21 | 2024-07-10 | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518150A JP2021518150A (ja) | 2021-08-02 |
| JPWO2019183248A5 true JPWO2019183248A5 (https=) | 2022-03-29 |
| JP2021518150A5 JP2021518150A5 (https=) | 2022-03-29 |
| JP7520719B2 JP7520719B2 (ja) | 2024-07-23 |
Family
ID=66001381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551263A Active JP7520719B2 (ja) | 2018-03-21 | 2019-03-20 | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
| JP2024110895A Pending JP2024138410A (ja) | 2018-03-21 | 2024-07-10 | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024110895A Pending JP2024138410A (ja) | 2018-03-21 | 2024-07-10 | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12600984B2 (https=) |
| EP (2) | EP3768846B1 (https=) |
| JP (2) | JP7520719B2 (https=) |
| KR (1) | KR20210016330A (https=) |
| CN (2) | CN112154208B (https=) |
| AU (2) | AU2019240068B2 (https=) |
| CA (1) | CA3093346A1 (https=) |
| DK (1) | DK3768846T5 (https=) |
| ES (1) | ES2950736T3 (https=) |
| FI (1) | FI3768846T3 (https=) |
| LT (1) | LT3768846T (https=) |
| SG (1) | SG11202009009UA (https=) |
| WO (1) | WO2019183248A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019183248A1 (en) * | 2018-03-21 | 2019-09-26 | Nature Technology Corporation | Viral and non-viral nanoplasmid vectors with improved production |
| US20220042038A1 (en) * | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| GB2700048B (en) | 2019-09-18 | 2026-03-04 | Aldevron Llc | synthetic dna vectors and method of use |
| JP7833134B2 (ja) * | 2020-03-11 | 2026-03-19 | アルデブロン，エル．エル．シー． | 細菌宿主株 |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| CA3223292A1 (en) | 2021-06-25 | 2022-12-29 | Laura Van Lieshout | Adeno-associated virus packaging systems |
| US20250114452A1 (en) | 2021-08-04 | 2025-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
| CN114045305B (zh) * | 2021-10-15 | 2023-03-24 | 深圳市深研生物科技有限公司 | 多转座子系统 |
| WO2023114901A2 (en) | 2021-12-15 | 2023-06-22 | Oxford Biomedica Solutions Llc | Methods and compositions for the production of adeno-associated virus |
| WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| US20250354159A1 (en) * | 2022-06-13 | 2025-11-20 | Nanjing GenScript Biotech Co., Ltd. | Wild-type-mutant pi protein switching expression system capable of increasing efficiency of preparing screening-tag-free plasmid |
| JP2025525583A (ja) | 2022-07-19 | 2025-08-05 | ランパート バイオサイエンス インコーポレイテッド | 非免疫原性環状非ウイルス性ｄｎａベクター |
| CN117305339B (zh) * | 2023-11-30 | 2024-02-06 | 苏州左旋星生物科技有限公司 | 优化大肠杆菌基因编辑的载体及其应用 |
| WO2025160245A1 (en) | 2024-01-25 | 2025-07-31 | Aldevron, L.L.C. | Viral and non-viral nanoplasmid vectors with improved production |
| WO2025231315A2 (en) | 2024-05-03 | 2025-11-06 | Aldevron, L.L.C. | Bacterial host strains |
| WO2026076187A1 (en) * | 2024-10-03 | 2026-04-09 | Aldevron, L.L.C. | Compositions and methods for microbial production of antibiotic-free closed-ended linear dna |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04197185A (ja) * | 1990-11-28 | 1992-07-16 | Mitsui Toatsu Chem Inc | 酵母発現ベクター及びこれを用いた誘導的発現 |
| GB9506051D0 (en) * | 1995-03-24 | 1995-05-10 | Univ Singapore | Gene expression |
| FR2738842B1 (fr) | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
| US7279313B2 (en) | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| US5922583A (en) | 1995-10-17 | 1999-07-13 | Biostar Inc. | Methods for production of recombinant plasmids |
| US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| JP2004267001A (ja) * | 2000-08-16 | 2004-09-30 | Kansai Tlo Kk | トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法 |
| UY26317A1 (es) * | 2000-08-30 | 2000-10-31 | Alfonso Cayota Carlos Pritsch | Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo |
| FR2821855B1 (fr) | 2001-03-09 | 2004-04-02 | Cayla | Genes synthetiques et plasmides bacteriens depourvus de cpg |
| CA2794446C (en) * | 2001-04-04 | 2015-09-08 | Genencor International, Inc. | Uncoupled productive and catabolic host cell pathways |
| US20060088837A1 (en) * | 2002-04-26 | 2006-04-27 | Kazunari Taira | Expression system for stem-loop rna molecule having rnai effect |
| WO2005003359A1 (ja) * | 2003-07-08 | 2005-01-13 | Japan Science And Technology Corporation | トランスジェニック生物を作製する方法およびシステム |
| GB0327056D0 (en) | 2003-11-20 | 2003-12-24 | Cobra Biolog Ltd | Plasmid maintenance |
| MX2007001889A (es) | 2004-08-19 | 2007-05-09 | Nature Technology Corp | Proceso para la fermentacion de adn de plasmido. |
| CA2577519A1 (en) * | 2004-08-23 | 2006-03-30 | Nucleonics, Inc. | Multiple rna polymerase iii promoter expression constructs |
| TWI311152B (en) | 2004-09-17 | 2009-06-21 | Boehringer Ingelheim Rcv Gmbh & Co K | Host-vector system for antibiotic-free cole1 plasmid propagation |
| US9018012B2 (en) | 2005-01-20 | 2015-04-28 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| EP1921140B1 (en) | 2005-07-05 | 2011-12-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Mutant transposon vector and use thereof |
| US9017966B2 (en) | 2007-05-23 | 2015-04-28 | Nature Technology Corporation | E. coli plasmid DNA production |
| EP2152889B1 (en) * | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| ES2651911T3 (es) * | 2007-08-14 | 2018-01-30 | Commonwealth Scientific And Industrial Research Organisation | Métodos mejorados de silenciamiento génico |
| US9045759B2 (en) | 2009-01-21 | 2015-06-02 | James Arthur Williams | DNA plasmids with improved copy number |
| US9012226B2 (en) | 2009-03-13 | 2015-04-21 | Nature Technology Corporation | Bacterial strains with improved plasmid stability |
| US9506082B2 (en) | 2010-04-12 | 2016-11-29 | Nature Technology Corporation | Eukaryotic expression vectors resistant to transgene silencing |
| EP2788483B1 (en) * | 2011-12-07 | 2018-06-27 | Glenmark Pharmaceuticals S.A. | Expression cassette |
| US9550998B2 (en) * | 2012-08-29 | 2017-01-24 | Nature Technology Corporation | DNA plasmids with improved expression |
| US20150322439A1 (en) * | 2012-11-19 | 2015-11-12 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
| CA2914604A1 (en) * | 2013-06-06 | 2014-12-11 | Novartis Ag | Influenza virus reassortment |
| WO2017025447A1 (en) | 2015-08-10 | 2017-02-16 | Curevac Ag | Method of increasing the replication of a circular dna molecule |
| US11230720B2 (en) | 2015-10-14 | 2022-01-25 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
| WO2019183248A1 (en) | 2018-03-21 | 2019-09-26 | Nature Technology Corporation | Viral and non-viral nanoplasmid vectors with improved production |
| US20220042038A1 (en) * | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
-
2019
- 2019-03-20 WO PCT/US2019/023209 patent/WO2019183248A1/en not_active Ceased
- 2019-03-20 EP EP19715345.5A patent/EP3768846B1/en active Active
- 2019-03-20 AU AU2019240068A patent/AU2019240068B2/en active Active
- 2019-03-20 SG SG11202009009UA patent/SG11202009009UA/en unknown
- 2019-03-20 DK DK19715345.5T patent/DK3768846T5/da active
- 2019-03-20 KR KR1020207030139A patent/KR20210016330A/ko not_active Ceased
- 2019-03-20 JP JP2020551263A patent/JP7520719B2/ja active Active
- 2019-03-20 FI FIEP19715345.5T patent/FI3768846T3/fi active
- 2019-03-20 LT LTEPPCT/US2019/023209T patent/LT3768846T/lt unknown
- 2019-03-20 CN CN201980034026.9A patent/CN112154208B/zh active Active
- 2019-03-20 EP EP22194460.6A patent/EP4151735A1/en active Pending
- 2019-03-20 CA CA3093346A patent/CA3093346A1/en active Pending
- 2019-03-20 CN CN202510450562.4A patent/CN120249340A/zh active Pending
- 2019-03-20 ES ES19715345T patent/ES2950736T3/es active Active
-
2020
- 2020-09-18 US US17/026,101 patent/US12600984B2/en active Active
-
2024
- 2024-07-10 JP JP2024110895A patent/JP2024138410A/ja active Pending
-
2025
- 2025-05-08 AU AU2025203312A patent/AU2025203312A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518150A5 (https=) | ||
| JPWO2019183248A5 (https=) | ||
| CN112513250A (zh) | 用于跟踪和操纵细胞rna的融合蛋白和融合核糖核酸 | |
| JP7833134B2 (ja) | 細菌宿主株 | |
| WO2011038187A1 (en) | Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom | |
| CN110785495A (zh) | 腺相关病毒载体的生产方法 | |
| WO2019062522A1 (zh) | 一种sgRNA、改造的Cas9蛋白及试剂盒 | |
| WO2022116815A1 (zh) | 一种慢病毒稳定包装细胞系及其制备方法 | |
| US20250066811A1 (en) | DNA Amplification Method Using CARE Elements | |
| CN117568348B (zh) | 用于维持多聚腺苷质粒单体超螺旋的基因及其应用 | |
| CN119137273A (zh) | 包括工程化核内小RNA（snRNA）的组合物和方法 | |
| CN116411024A (zh) | 用于生产重组腺相关病毒的质粒系统 | |
| CN111218477B (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| US20220177529A1 (en) | Fusion protein for enhancing gene editing and use thereof | |
| EP4650453A1 (en) | Antibiotic-free miniplasmid, and preparation method therefor and use thereof | |
| US20230416777A1 (en) | Moloney murine leukemia virus-based self-inactivating vector and applications thereof | |
| CN111518812B (zh) | 一种编辑绵羊FGF5基因实现选择性剪接的sgRNA、成套核酸分子和应用 | |
| EP3792367A1 (en) | Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest | |
| JPWO2021226008A5 (https=) | ||
| JPWO2021183827A5 (https=) | ||
| WO2023060589A1 (zh) | 多转座子系统 | |
| JP4450438B2 (ja) | タンパク質の増強された生産方法 | |
| CN116023513B (zh) | 一种适用于大鼠肝细胞特异性感染腺相关病毒突变体 | |
| CN116284262B (zh) | 高效感染ht-22细胞的腺相关病毒突变体 | |
| CN102533741B (zh) | 猪假attp位点及其用途 |